[HTML][HTML] Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational …
TM Caparrotta, AM Greenhalgh, K Osinski, RM Gifford… - Diabetes Therapy, 2021 - Springer
Introduction Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
[HTML][HTML] Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational …
TM Caparrotta, AM Greenhalgh, K Osinski… - Diabetes …, 2021 - ncbi.nlm.nih.gov
Methods A pre-planned and registered ((International PROSPEctive Register Of Systematic
Reviews) PROSPERO registration CRD42019160792) systematic review of population …
Reviews) PROSPERO registration CRD42019160792) systematic review of population …
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.
TM Caparrotta, AM Greenhalgh, K Osinski… - Diabetes …, 2021 - search.ebscohost.com
Introduction: Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
[DOC][DOC] Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies
TM Caparrotta, AM Greenhalgh, K Osinski, RM Gifford… - pure.ed.ac.uk
Introduction: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.
TM Caparrotta, AM Greenhalgh, K Osinski… - … and Education of …, 2021 - europepmc.org
Methods A pre-planned and registered ((International PROSPEctive Register Of Systematic
Reviews) PROSPERO registration CRD42019160792) systematic review of population …
Reviews) PROSPERO registration CRD42019160792) systematic review of population …
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.
TM Caparrotta, AM Greenhalgh, K Osinski… - Diabetes …, 2021 - go.gale.com
Introduction Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
TM Caparrotta, AM Greenhalgh, K Osinski… - Diabetes …, 2021 - search.proquest.com
Methods A pre-planned and registered ((International PROSPEctive Register Of Systematic
Reviews) PROSPERO registration CRD42019160792) systematic review of population …
Reviews) PROSPERO registration CRD42019160792) systematic review of population …
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
TM Caparrotta, AM Greenhalgh, K Osinski… - Diabetes …, 2021 - research.ed.ac.uk
METHODS: A pre-planned and registered ((International PROSPEctive Register Of
Systematic Reviews) PROSPERO registration CRD42019160792) systematic review of …
Systematic Reviews) PROSPERO registration CRD42019160792) systematic review of …
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
TM Caparrotta, AM Greenhalgh… - … and education of …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.
TM Caparrotta, AM Greenhalgh, K Osinski… - … and Education of …, 2021 - europepmc.org
Methods A pre-planned and registered ((International PROSPEctive Register Of Systematic
Reviews) PROSPERO registration CRD42019160792) systematic review of population …
Reviews) PROSPERO registration CRD42019160792) systematic review of population …